Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tans...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiao‐Zhong, Gao, Ying, Huang, Sheng, Chen, Zhuang‐Zhong, Sun, Ling‐Ling, Liu, Jia‐Hui, Chen, Han‐Rui, Yu, Ling, Zhang, Jia‐Xing, Lin, Li‐Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://www.ncbi.nlm.nih.gov/pubmed/31268205
http://dx.doi.org/10.1002/ptr.6392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://www.ncbi.nlm.nih.gov/pubmed/31268205
http://dx.doi.org/10.1002/ptr.6392

Ejemplares similares